Third Harmonic Bio Announces Plan of Liquidation and Dissolution

Core Viewpoint - Third Harmonic Bio, Inc. has approved a Plan of Liquidation and Dissolution, aiming to maximize stockholder value through asset sales and cash distributions to shareholders [1][2][3] Group 1: Plan of Liquidation and Dissolution - The Board of Directors unanimously approved the dissolution and liquidation of the Company, pending stockholder approval, with a meeting scheduled for June 5, 2025 [3] - The initial distribution to stockholders is expected to be between approximately $246.6 million and $255.4 million, translating to about $5.13 to $5.33 per share, anticipated in the third quarter of 2025 [1][3] - The Company plans to sell its assets, including the THB335 program, to maximize value for stockholders during the liquidation process [1][2] Group 2: Financial Estimates and Provisions - The total estimated distribution to stockholders could range from approximately $246.6 million to $259.8 million, or about $5.13 to $5.42 per share, depending on the outcomes of asset sales [3] - The Company will establish a reserve to cover expenses and liabilities during the dissolution process, ensuring sufficient funds are available to meet obligations [3] Group 3: Management Statements - The CEO emphasized the management team's commitment to maximizing asset value and acting in the best interest of patients and shareholders [2] - The Board retains the right to abandon the Plan of Dissolution at any time before it becomes effective if deemed in the best interest of the Company and its stockholders [4]